Skip to main content

Table 2 Logistic regression analysis: variables determining the decision to prescribe PEGV with or without SSA therapy (dependent variable)

From: Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

GH at baseline (μg/L) 1.015 (0.983-1.043) 1.047
IGF-I SDS at baseline 1.003 (0.999-1.007) 0.097
Δ IGF IaSDS 1.446 (1.153-1.814) 0.001
Detectable adenoma at baseline b 13.757 (2.547-74.307) 0.002
  1. Abbreviations: CI confidence intervals, OR odds ratios, PEGV pegvisomant, SSA somatostatin analogs.
  2. a SDS observed at diagnosis minus SDS observed at baseline.
  3. b Includes patients who had not had surgery and those who had undergone surgery but presented residual tumor at baseline.